Isatuximab in multiple myeloma-Reference-Cited by-同舟云学术

Isatuximab in multiple myeloma

Published:2023-03-24 Issue:4 Volume:23 Page:315-318
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Martino Enrica Antonia¹,Bruzzese Antonella¹,Iaccino Enrico²,Mendicino Francesco¹,Mimmi Selena²,Lucia Eugenio¹,Olivito Virginia¹,Neri Antonino³,Morabito Fortunato⁴,Vigna Ernesto¹,Gentile Massimo¹⁵^ORCID

Affiliation:

1. Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy

2. Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Italy

3. Scientific Directorate IRCCS of Reggio Emilia, EmiliaRomagna, Reggio Emilia, Italy

4. Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy

5. Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2193289

Reference24 articles.

1. Immunotherapy of Multiple Myeloma: Promise and Challenges

2. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

3. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

4. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

5. Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selinexor in multiple myeloma;Expert Opinion on Pharmacotherapy;2024-03-03

2. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials;Frontiers in Oncology;2023-12-07

3. Teclistamab‐cqyv in multiple myeloma;European Journal of Haematology;2023-10-17

4. Correction;Expert Opinion on Biological Therapy;2023-07-07

5. Remission of social behavior impairment by oral administration of a precursor of NAD in CD157, but not in CD38, knockout mice;Frontiers in Immunology;2023-05-04